{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:14:32Z","timestamp":1752282872967},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1097\/wnf.0b013e318067bcc4","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T07:09:17Z","timestamp":1236236957000},"page":"19-24","source":"Crossref","is-referenced-by-count":8,"title":["Conversion From Dopamine Agonists to Cabergoline"],"prefix":"10.1097","volume":"31","author":[{"given":"Gurutz","family":"Linazasoro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210203","first-page":"369","article-title":"Comparative review of dopamine receptor agonists in Parkinson's disease.","volume":"5","author":"Uitti","year":"1996","journal-title":"Drugs"},{"key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00023210-199912060-00006","article-title":"Cabergoline. A review of its efficacy in the treatment of Parkinson's disease.","volume":"12","author":"Wiseman","year":"1999","journal-title":"CNS Drugs"},{"issue":"suppl 1","key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","article-title":"Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double blind levodopa controlled trial.","volume":"55","author":"Rinne","year":"1998","journal-title":"Drugs"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00002826-199619030-00002","article-title":"Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.","volume":"19","author":"Ahlskog","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.46.4.1062","article-title":"Multicenter, placebo-controlled trial of cagbergoline taken once daily in the treatment of Parkinson's disease.","volume":"46","author":"Hutton","year":"1996","journal-title":"Neurology"},{"key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1212\/WNL.43.12.2587","article-title":"Cabergoline in Parkinson's disease: long-term follow-up.","volume":"43","author":"Lera","year":"1993","journal-title":"Neurology"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1212\/WNL.35.5.749","article-title":"Chronic agonist therapy for Parkinson's disease: a five-year study of bromocriptine and pergolide.","volume":"35","author":"Goetz","year":"1985","journal-title":"Neurology"},{"key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/WNL.39.8.1121","article-title":"Agonist substitution in advanced Parkinson's disease.","volume":"39","author":"Goetz","year":"1989","journal-title":"Neurology"},{"key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.52.6.1227","article-title":"Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow?","volume":"52","author":"Goetz","year":"1999","journal-title":"Neurology"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s007020170097","article-title":"Switching from pergolide to pramipexole in patients with Parkinson's disease.","volume":"108","author":"Hanna","year":"2001","journal-title":"J Neural Transm"},{"issue":"suppl 3","key":"R11-3-20210203","first-page":"133","article-title":"Acute versus gradual pramipexole to ropinirole switch.","volume":"15","author":"Hauser","year":"2000","journal-title":"Mov Disord"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s007020050212","article-title":"An overnight switch to ropinirole therapy in patients with Parkinson's disease.","volume":"106","author":"Canesi","year":"1999","journal-title":"J Neural Transm"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00002826-200111000-00006","article-title":"Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.","volume":"24","author":"Gimenez Roldan","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1468-1331.1999.650618.x","article-title":"Equivalent doses of ropinirole and bromocriptine Letter.","volume":"6","author":"Jost","year":"1999","journal-title":"Eur J Neurol"},{"key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00415-004-0328-0","article-title":"Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.","volume":"251","year":"2004","journal-title":"J Neurol"},{"key":"R16-3-20210203","first-page":"A279","article-title":"The tolerability and efficacy of pramipexole in patients with idiopathic Parkinson's disease previously on bromocriptine, pergolide or cabergoline.","volume":"50","author":"Shulman","year":"1998","journal-title":"Neurology"},{"key":"R17-3-20210203","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00702-004-0110-6","article-title":"Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.","volume":"111","author":"Shiraishi","year":"2004","journal-title":"J Neural Transm"},{"key":"R18-3-20210203","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of Lewy body to the pathogenesis of Parkinson's disease.","volume":"51","author":"Gibb","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","article-title":"Intermittent vs continuous levodopa administration in patients with advanced Parkinson's disease: a clinical and pharmacokinetic study.","volume":"62","author":"Stocchi","year":"2005","journal-title":"Arch Neurol"},{"key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tips.2005.06.007","article-title":"New ideas on the pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: age, genes and neural plasticity.","volume":"26","author":"Linazasoro","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/mds.20210","article-title":"Switching from ergot to non-ergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.","volume":"19","author":"Grosset","year":"2004","journal-title":"Mov Disord"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"R23-3-20210203","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","article-title":"Herat valvular disease in patients with Parkinson's disease treated with high dose pergolide.","volume":"61","author":"Van Camp","year":"2003","journal-title":"Neurology"},{"key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","article-title":"Pergolide use in Parkinson's disease is associated with cardiac valve regurgitation.","volume":"63","author":"Baseman","year":"2004","journal-title":"Neurology"},{"key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","article-title":"Valvular heart disease in patients taking pergolide.","volume":"77","author":"Pritchett","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot dopamine agonists.","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord"},{"key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJM200511033531822","article-title":"Cabergoline-related severe restrictive mitral regurgitation.","volume":"353","author":"Pinero","year":"2005","journal-title":"N Engl J Med"},{"key":"R28-3-20210203","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","article-title":"Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study.","volume":"21","author":"Peralta","year":"2006","journal-title":"Mov Disord"},{"key":"R29-3-20210203","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","article-title":"Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.","volume":"67","author":"Yamamoto","year":"2006","journal-title":"Neurology"},{"key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease.","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation.","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200801000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:41:43Z","timestamp":1618278103000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200801000-00003"}},"subtitle":["An Open-Label Trial in 128 Patients With Advanced Parkinson Disease"],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318067bcc4","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}